Substituted Amide Btk Inhibitors for Autoimmune Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases, such as systemic lupus erythematosus and rheumatoid arthritis, often have limitations in effectively targeting Bruton's Tyrosine Kinase (Btk) activity, which is crucial for B-cell activation and osteoclast function, leading to incomplete disease suppression and potential side effects.
Innovation Solution
Development of specific substituted amides and related compounds that inhibit Btk activity, including pharmaceutical compositions and methods for their use in treating diseases responsive to Btk inhibition, offering potent inhibition of Btk kinase activity with improved therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune and inflammatory diseases are used, then disease symptoms can be managed, but Btk activity is not effectively inhibited leading to incomplete disease suppression and potential side effects
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of Btk inhibitors through various substituents (R1-R6, L, G, X) on the pyrid-2-one core structure. These structural parameter changes enable more effective and specific inhibition of Btk activity, improving disease suppression while reducing off-target effects and side effects associated with less specific inhibitors.
2Adaptability or versatility
If protein-based therapeutics such as Rituxan are used to deplete B-cells, then B-cell mediated pathogenic activity can be inhibited, but the treatment approach lacks specificity for Btk inhibition
Solution Approach 1:
The patent applies local quality by designing small molecule compounds with specific functional groups and substituents positioned at precise locations on the pyrid-2-one core structure. This localized structural design enables the compounds to specifically target and inhibit Btk with high precision, unlike broad-acting protein-based therapeutics that deplete all B-cells regardless of their pathogenic state.
3Reliability
If Btk inhibitors are developed to improve disease suppression, then therapeutic efficacy increases, but compound complexity and development challenges arise
Solution Approach 1:
The patent applies universality by creating a pyrid-2-one based inhibitor scaffold that can effectively target Btk while allowing for various substituent modifications. This universal core structure provides a platform for developing multiple related compounds with different pharmacokinetic and pharmacodynamic properties, enabling optimization of therapeutic efficacy without proportionally increasing structural complexity.
Data Source
AI summary
At least one chemical entity chosen from compounds of Formula (1) and pharmaceutically acceptable salts, solvat